{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:04:10Z","timestamp":1740107050085,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["2020MFDS171","2020MFDS171","2020MFDS171","2020MFDS171"],"award-info":[{"award-number":["2020MFDS171","2020MFDS171","2020MFDS171","2020MFDS171"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Carfilzomib, commonly used for relapsed\/refractory multiple myeloma (RRMM), has been associated with various adverse events in randomized controlled trials (RCTs). However, real-world safety data for a more diverse population are needed, as carfilzomib received expedited approval. This study aimed to evaluate carfilzomib\u2019s safety in Korea by comparing new users of KRd (carfilzomib, lenalidomide, and dexamethasone) to Rd (lenalidomide and dexamethasone) using a nationwide administrative claims database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The retrospective cohort study utilized target trial emulation, focusing on adverse events in various organ systems similar to the ASPIRE trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study included 4,580 RRMM patients between 2007 and 2020, and the KRd group showed significantly higher risks of hematologic adverse events (anemia, neutropenia, thrombocytopenia) and some non-hematologic adverse events (cough, hypokalemia, constipation, hypertension, heart failure) compared to the Rd group. Among non-hematologic adverse events, cardiovascular events (heart failure [HR 2.04; 95% CI 1.24\u20133.35], hypertension [HR 1.58; 95% CI 1.15\u20132.17]) had the highest risk in the KRd group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The safety profile of carfilzomib in Korean patients was similar to previous RCTs. Therefore, caution should be exercised when using carfilzomib in Asian individuals with RRMM due to the increased risk of cardiovascular adverse events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05800-8","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:02:07Z","timestamp":1716224527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Target trial emulation of carfilzomib safety among patients with relapsed\/refractory multiple myeloma using a nationwide observational data in Korea"],"prefix":"10.1007","volume":"150","author":[{"given":"Hyun Kyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Wha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Mi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"issue":"5","key":"5800_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/ene.15284","volume":"29","author":"N Ahn","year":"2022","unstructured":"Ahn N, Nolde M, G\u00fcnter A, G\u00fcntner F, Gerlach R, Tauscher M et al (2022) Emulating a target trial of proton pump inhibitors and dementia risk using claims data. Eur J Neurol 29(5):1335\u20131343. https:\/\/doi.org\/10.1111\/ene.15284","journal-title":"Eur J Neurol"},{"issue":"1","key":"5800_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cam4.3568","volume":"10","author":"R Bishnoi","year":"2021","unstructured":"Bishnoi R, Xie Z, Shah C, Bian J, Murthy HS, Wingard JR et al (2021) Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. Cancer Med 10(1):70\u201378. https:\/\/doi.org\/10.1002\/cam4.3568","journal-title":"Cancer Med"},{"issue":"1","key":"5800_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27\u201338. https:\/\/doi.org\/10.1016\/s1470-2045(15)00464-7","journal-title":"Lancet Oncol"},{"issue":"4","key":"5800_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s12185-019-02704-z","volume":"110","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Moreau P, Iida S, Huang S-Y, Takezako N, Chng WJ et al (2019) Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Int J Hemat 110(4):466\u2013473. https:\/\/doi.org\/10.1007\/s12185-019-02704-z","journal-title":"Trials. Int J Hemat"},{"issue":"4","key":"5800_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cncr.32601","volume":"126","author":"B Fakhri","year":"2020","unstructured":"Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM (2020) Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer 126(4):808\u2013813. https:\/\/doi.org\/10.1002\/cncr.32601","journal-title":"Cancer"},{"issue":"1","key":"5800_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2016.176","volume":"31","author":"R H\u00e1jek","year":"2017","unstructured":"H\u00e1jek R, Masszi T, Petrucci MT, Palumbo A, Rosi\u00f1ol L, Nagler A et al (2017) A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 31(1):107\u2013114. https:\/\/doi.org\/10.1038\/leu.2016.176","journal-title":"Leukemia"},{"issue":"8","key":"5800_CR7","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM (2016) Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol 183(8):758\u2013764. https:\/\/doi.org\/10.1093\/aje\/kwv254","journal-title":"Am J Epidemiol"},{"issue":"17","key":"5800_CR8","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.Ccr-13-0755","volume":"19","author":"TM Herndon","year":"2013","unstructured":"Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD et al (2013) U.S Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 19(17):4559\u20134563. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0755","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5800_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3904\/kjim.2015.408","volume":"31","author":"J Hong","year":"2016","unstructured":"Hong J, Lee JH (2016) Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med 31(5):820\u2013834. https:\/\/doi.org\/10.3904\/kjim.2015.408","journal-title":"Korean J Intern Med"},{"key":"5800_CR10","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.2147\/ott.s317570","volume":"14","author":"H Imtiaz","year":"2021","unstructured":"Imtiaz H, Khan M, Ehsan H, Wahab A, Rafae A, Khan AY et al (2021) Efficacy and toxicity profile of carfilzomib-based regimens for treatment of newly diagnosed multiple myeloma: a systematic review. Onco Targets Ther 14:4941\u20134960. https:\/\/doi.org\/10.2147\/ott.s317570","journal-title":"Onco Targets Ther"},{"issue":"20","key":"5800_CR11","doi-asserted-by":"publisher","first-page":"13560","DOI":"10.3390\/ijerph192013560","volume":"19","author":"HY Jang","year":"2022","unstructured":"Jang HY, Lee HK, Kim CJ, Yoon S-S, Kim I-W, Oh JM (2022) Carfilzomib\u2019s real-world safety outcomes in Korea: target trial emulation study using electronic health records. Int J Environ Res Public Health 19(20):13560. https:\/\/doi.org\/10.3390\/ijerph192013560","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"5800_CR12","doi-asserted-by":"publisher","first-page":"R135","DOI":"10.1530\/ec-18-0109","volume":"7","author":"E Kardalas","year":"2018","unstructured":"Kardalas E, Paschou SA, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A (2018) Hypokalemia: a clinical update. Endocr Connect 7(4):R135\u2013R146. https:\/\/doi.org\/10.1530\/ec-18-0109","journal-title":"Endocr Connect"},{"issue":"2","key":"5800_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1476","volume":"5","author":"Y Kawaji-Kanayama","year":"2022","unstructured":"Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N et al (2022) Prognostic impact of resistance to bortezomib and\/or lenalidomide in carfilzomib-based therapies for relapsed\/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. Cancer Reports 5(2):e1476. https:\/\/doi.org\/10.1002\/cnr2.1476","journal-title":"Cancer Reports"},{"issue":"24","key":"5800_CR14","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.2217\/fon-2022-0259","volume":"18","author":"A Kawasaki","year":"2022","unstructured":"Kawasaki A, Murakami H, Chou T, Matsushita M, Kizaki M (2022) Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma. Future Oncol 18(24):2661\u20132674. https:\/\/doi.org\/10.2217\/fon-2022-0259","journal-title":"Future Oncol"},{"issue":"3","key":"5800_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4082\/kjfm.20.0062","volume":"41","author":"S Kim","year":"2020","unstructured":"Kim S, Kim M-S, You S-H, Jung S-Y (2020) Conducting and reporting a clinical research using Korean healthcare claims database. Korean J Fam Med 41(3):146\u2013152. https:\/\/doi.org\/10.4082\/kjfm.20.0062","journal-title":"Korean J Fam Med"},{"key":"5800_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04407-0","author":"JH Lee","year":"2021","unstructured":"Lee JH, Park Y, Kang K-W, Lee J-J, Lee HS, Eom H-S et al (2021) Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-021-04407-0","journal-title":"Ann Hematol"},{"issue":"9","key":"5800_CR17","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B (2020) Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist 25(9):e1406\u2013e1413. https:\/\/doi.org\/10.1634\/theoncologist.2020-0141","journal-title":"Oncologist"},{"issue":"41","key":"5800_CR18","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"unstructured":"National Cancer Center 2023 Annual Report of Cancer Statistics in Korea in 2020. https:\/\/ncc.re.kr\/cancerStatsView.ncc?bbsnum=638&searchKey=total&searchValue=&pageNum=1. Accessed 13 June 2023","key":"5800_CR19"},{"issue":"5","key":"5800_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/jcph.850","volume":"57","author":"Y Ou","year":"2017","unstructured":"Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K et al (2017) Population pharmacokinetics and exposure-response relationship of carfilzomib in patients with multiple myeloma. J Clin Pharmacol 57(5):663\u2013677. https:\/\/doi.org\/10.1002\/jcph.850","journal-title":"J Clin Pharmacol"},{"unstructured":"Parsons LS 2001 Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. https:\/\/support.sas.com\/resources\/papers\/proceedings\/proceedings\/sugi26\/p214-26.pdf. Accessed 1 January 2017","key":"5800_CR21"},{"issue":"1","key":"5800_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hon.2820","volume":"39","author":"S Rocchi","year":"2021","unstructured":"Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, Di Giovanni BC et al (2021) A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed\/refractory multiple myeloma. Hematol Oncol 39(1):41\u201350. https:\/\/doi.org\/10.1002\/hon.2820","journal-title":"Hematol Oncol"},{"issue":"5","key":"5800_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/resp.14001","volume":"26","author":"M Rossides","year":"2021","unstructured":"Rossides M, Kullberg S, Di Giuseppe D, Eklund A, Grunewald J, Askling J et al (2021) Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: a retrospective \u2018target trial\u2019 emulated with Swedish real-world data. Respirology 26(5):452\u2013460. https:\/\/doi.org\/10.1111\/resp.14001","journal-title":"Respirology"},{"issue":"2","key":"5800_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/ejh.13523","volume":"106","author":"C Scheid","year":"2021","unstructured":"Scheid C, Blau IW, Sellner L, Ratsch BA, Basic E (2021) Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database. Eur J Haematol 106(2):148\u2013157. https:\/\/doi.org\/10.1111\/ejh.13523","journal-title":"Eur J Haematol"},{"key":"5800_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3389\/fphar.2019.01163","volume":"10","author":"EC So","year":"2019","unstructured":"So EC, Liu PY, Lee CC, Wu SN (2019) High Effectiveness in Actions of Carfilzomib on Delayed-Rectifier K(+) Current and on Spontaneous Action Potentials. Front Pharmacol 10:1163. https:\/\/doi.org\/10.3389\/fphar.2019.01163","journal-title":"Front Pharmacol"},{"issue":"2","key":"5800_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/nejmoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142\u2013152. https:\/\/doi.org\/10.1056\/nejmoa1411321","journal-title":"N Engl J Med"},{"issue":"6","key":"5800_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/dom.14353","volume":"23","author":"Y Takeuchi","year":"2021","unstructured":"Takeuchi Y, Kumamaru H, Hagiwara Y, Matsui H, Yasunaga H, Miyata H et al (2021) Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database. Diabetes Obes Metab 23(6):1379\u20131388. https:\/\/doi.org\/10.1111\/dom.14353","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"5800_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","volume":"101","author":"I Turesson","year":"2018","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O (2018) Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol 101(2):237\u2013244. https:\/\/doi.org\/10.1111\/ejh.13083","journal-title":"Eur J Haematol"},{"issue":"3","key":"5800_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ, Clasen S, Hwang W-T, Garfall A, Vogl DT, Carver J et al (2018) Carfilzomib-associated cardiovascular adverse events. JAMA Oncol 4(3):e174519. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4519","journal-title":"JAMA Oncol"},{"issue":"11","key":"5800_CR30","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2337\/dc20-1890","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Yan Y et al (2020) Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care 43(11):2859\u20132869. https:\/\/doi.org\/10.2337\/dc20-1890","journal-title":"Diabetes Care"},{"key":"5800_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.735466","volume":"8","author":"Y Zhai","year":"2021","unstructured":"Zhai Y, Ye X, Hu F, Xu J, Guo X, Cao Y et al (2021) Cardiovascular toxicity of carfilzomib: the real-world evidence based on the adverse event reporting system database of the FDA, the United States. Front Cardiovasc Med 8:735466. https:\/\/doi.org\/10.3389\/fcvm.2021.735466","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"5800_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2020-217200","volume":"79","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Lyu H, Solomon DH, Yoshida K (2020) Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework. Ann Rheum Dis 79(7):883\u2013890. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217200","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05800-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:25:12Z","timestamp":1717989912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05800-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["5800"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05800-8","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Ethical approval was waived by the Institutional Review Board of Seoul National University (IRB No. E2101\/001\u2013003) in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The datasets generated and analyzed in the current study are not publicly available because the Korea Health Insurance Review and Assessment Service only allows access to restricted researchers who have been approved for a specific study protocol. Researchers can apply for the data from the Korea Health Insurance Review and Assessment Service on research purposes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}],"article-number":"266"}}